TrialCancer gene therapy2022

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.

Elyssa Sliheet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.